Search Results - andrew+sinkoe

3 Results

Sort By:

Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies

Summary: The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a liquid biopsy diagnostic assay capable of detecting loss of heterozygosity (LOH) and somatic mutations in genes important for antigen processing and presentation and interferon-γ response pathways. Description of Technology: Immunotherapy is...

Published: 9/13/2024 | Inventor(s): Scott Norberg, Andrew Sinkoe, Xiaolin Wu, James Gulley

Keywords(s):

Category(s): Application > Diagnostics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology

Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies

Published: 7/26/2024 | Inventor(s): Scott Norberg, Andrew Sinkoe, Xiaolin Wu, James Gulley

Keywords(s):

Category(s): Application > Diagnostics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology

Method for HLA LOH Detection in Liquid Biopsies

Abstract: Human leukocyte antigen (HLA) LOH (LOH) is a known resistance mechanism by which cancers evade T cell receptor-(TCR-)based immunotherapies. This class of therapies includes immune checkpoint inhibition (ICI, e.g., Pembrolizumab), engineered TCR (T cell receptor)-T cell adoptive transfer, tumor infiltrating lymphocytes (TIL), T-cell engagers,...

Published: 5/8/2024 | Inventor(s): Andrew Sinkoe, James Gulley, Cem Sievers

Keywords(s): Companion Diagnostic, Gulley, HLA, Human Leukocyte Antigen, ICI, Immune Checkpoint Inhibition, Immunotherapy, LOH, Loss of Heterozygosity, Sinkoe, T cell therapy

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Diagnostics